Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

ed 3% to $1,294 million for the 2007 full year due to lower alliance revenue associated with sales of the CYPHER stent and Altace. The decrease was partially offset by higher sales of Enbrel in the United States and Canada. Excluding the favorable impact of foreign exchange, worldwide Pharmaceuticals net revenue increased 6% for the 2007 fourth quarter and 8% for the 2007 full year.

Consumer Healthcare

Worldwide Consumer Healthcare net revenue increased 10% for the 2007 fourth quarter and 8% for the 2007 full year due primarily to an increase in sales of Advil(R), Advil(R) PM, Advil(R) Cold & Sinus, Centrum(R), Caltrate(R) and Chapstick(R), partially offset by lower sales of Dimetapp(R) and Robitussin(R) primarily due to the voluntary recall and replacement program initiated during the 2007 third quarter in connection with the redesign of dosing cups. Excluding the favorable impact of foreign exchange, worldwide

Consumer Healthcare net revenue increased 5% for the 2007 fourth quarter and full year.

Animal Health

Worldwide Animal Health net revenue increased 24% for the 2007 fourth quarter and 11% for the 2007 full year primarily due to higher sales of companion animal products, which included sales of our recently launched ProMeris(R) flea and tick products, as well as higher sales of livestock, equine and poultry products. Excluding the favorable impact of foreign exchange, worldwide Animal Health net revenue increased 17% for the 2007 fourth quarter and 7% for the 2007 full year.

2008 Earnings Guidance

The Company estimates pro forma diluted earnings per share for 2008 will be $3.35 to $3.49, a decrease of 1% to 5% versus 2007. This estimate reflects the impact of generic Protonix and certain assumptions about generic competition for Zosyn and Effexor. The 2008 estimate is considered pro forma as it excludes potential charges resulting from the Company's ongoing productivity initiatives. Net revenue in 2008 is expec
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  BioScrip, Inc. (NASDAQ: BIOS ) ... Jefferies 2013 Global Healthcare Conference to be held June ... Richard Smith , President and ... , Chief Financial Officer, will present on Monday, June ... About BioScrip BioScrip, Inc. provides comprehensive ...
(Date:5/23/2013)... Graphite Metallizing Corporation announces a ... in stainless steel pillow blocks. This series combines ... the application and installation versatility of pillow blocks. ... work exceptionally well when submerged in water, water-soluble ... as acids, alkalies, hydrocarbons, black liquor, and liquid ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... San Francisco, CA (PRWEB) May 23, 2013 ... do-it-yourselfers who encourage all types of inventions. They focus ... we’re now noticing this community gravitate toward bringing their ... community, the DIY Biology Movement, works on making projects ... sequencing the DNA of plants to make them glow ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... in over 60% of evaluable patients -, SEOUL, ... ) today reported interim data from an ongoing phase ... non-small cell,lung cancer (NSCLC). This open-label phase 2 trial ... IV NSCLC who have adenocarcinoma,histology and meet one of ...
... - A NASA-developed innovative process is making waves ... of new companies in the process. A new ... NASA Goddard Space Flight Center,s unique single-walled carbon ... high-quality, low-cost SWCNTs available commercially. , Potential ...
... Institute (TCI), a Los,Angeles-based DNA and genomics research ... new office in the heart of Boston,s legal ... effects of,chemical and toxic exposures on human health ... Reach Consulting, TCI now offers a,range of business, ...
Cached Biology Technology:Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 4NASA technology forms the basis for a new nanotechnology company 2Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
(Date:5/23/2013)... Neuron , the team reveal the interplay of brain ... by the Wellcome Trust and BBSRC. , By ... improve our perceptual abilities. While these changes can affect ... affect the fidelity of that response. , ... "When you communicate with others, you can make yourself ...
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2Tests lead to doubling of fuel cell life 2
... yeast, worms, and flies keeps blood sugar under control ... Cell Metabolism. The findings suggest therapeutic interventions for the ... 2 diabetes, which frequently arise with age, the researchers ... excess of the protein Sirt1 in cells of the ...
... hospital-acquired infections can persist for days and even ... including bed linens, computer keyboard covers and acrylic ... 105th General Meeting of the American Society for ... major cause of hospital-acquired infections in the United ...
... study in the July 18 issue of The Journal ... harmful than their unpigmented relatives. A group of scientists ... discovered that the molecules that give certain bugs their ... called neutrophils. , Scientists and clinicians have known for ...
Cached Biology News:Sea Ice May Be on Increase in the Antarctic 2